CortiCare, Inc.

CortiCare, Inc. provides advanced tele-EEG monitoring services, delivering 24/7 real-time EEG analysis. Their innovative solutions enhance the diagnosis and treatment of seizure disorders across diverse healthcare settings. CortiCare, Inc.

was founded in 2009 in Carlsbad, US, specializing in tele-EEG monitoring. The company has successfully completed a total of 2 deals, with their most recent deal occurring on August 15, 2023. David Roe serves as the CEO. CortiCare, Inc.

specializes in advanced tele-EEG monitoring services, providing real-time EEG analysis 24/7/365 for patients across various healthcare settings. Core offerings include continuous and intermittent remote EEG monitoring, crucial for detecting subtle non-convulsive seizures—over 90% of seizures in ICU settings exhibit no outward signs. Their services cater to private practices, community hospitals, teaching hospitals, and emergency departments, with a focus on improving patient outcomes through timely diagnosis and treatment adjustments. CortiCare has also pioneered in-home ambulatory video-EEG solutions, aiding in diagnosing seizure disorders and related conditions.

Their innovative CortiCap™ device simplifies electrode application, allowing rapid connection in as little as 15 minutes, thus enhancing service delivery in critical care environments. The company operates across multiple geographical markets, specifically targeting facilities in the United States that require specialized neurology services. CortiCare’s revenue model is based on subscription-based EEG monitoring services for healthcare facilities and private practices. This model enables ongoing engagement, allowing hospitals to extend diagnostic capabilities and enhance patient care.

Their flagship service includes real-time EEG monitoring and interpretation by board-certified neurophysiologists, ensuring timely reports integrated directly into electronic medical records (EMR). Additionally, CortiCare's in-home ambulatory EEG services are designed for both full-time monitoring and gap coverage, catering to specific patient needs. This transaction structure underscores the company's commitment to providing cost-effective, high-quality neurodiagnostic services, ensuring healthcare providers can rely on CortiCare for essential monitoring and support in critical care scenarios. CortiCare, Inc.

plans to expand its offerings by developing new products aimed at enhancing tele-EEG services. Recent funding received in August 2023 will support product innovations and market expansion into new regions requiring specialized neurology services. The company's strategy includes targeting additional healthcare facilities across the United States to broaden its service reach and meet the growing demand for EEG monitoring solutions. Following the exit of HCAP Partners from their stake, CortiCare is well-positioned for future growth.